Disseminated fusariosis in immunocompromised children: a case series and review of literature.
M P Riojas HernándezD Cisneros SaldañaD N Vaquera AparicioJosé Iván Castillo BejaranoA H Mascareñas de Los SantosH Villanueva-LozanoJ Treviño-Rangel Rogelio deM E De la O CavazosPublished in: Journal of chemotherapy (Florence, Italy) (2021)
In the era of antifungal prophylaxis for cancer patients, Fusarium genus has become the second leading cause of invasive fungal infections and mortality in this group of patients. The intrinsic resistance to antifungal agents and the patient's risk factors are the most important variables for prognosis and survival. Currently, the use of monotherapy in comparison to combined antifungal treatment information is scarce. In this report, we present a series of three cases of children with acute lymphoblastic leukemia and disseminated fusariosis categorized according to the European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG). Furthermore, we present a current literature review focused on treatment using monotherapy or combined antifungal treatment.
Keyphrases
- risk factors
- acute lymphoblastic leukemia
- candida albicans
- combination therapy
- randomized controlled trial
- case report
- type diabetes
- squamous cell carcinoma
- end stage renal disease
- clinical trial
- coronary artery disease
- ejection fraction
- intensive care unit
- open label
- peritoneal dialysis
- health information
- extracorporeal membrane oxygenation
- cell wall
- childhood cancer